论文部分内容阅读
笔者分析了我国医药行业的现状,并采用聚类分析方法,针对我国的医药行业的特点,依据医药行业上方公司的业绩对影响生物医药行业投资机会的因素进行了实证分析,进而展望我国医药行业的发展前景,并指出风险投资可能存在的切入点。 笔者发现产品的特性及其市场定位在医药行业公司经营的成败方面起到了关键的作用,只要产品性能好、市场定位合理,投资于化学制药、生物制药和中药业都可能获得成劝。在现阶段,影响该行业投资机会的主要因素是产品技术风险和市场风险。非专利和OTC药品、生物技术与中药,计算机相联系的生物芯片等领域,投资者应该重点关注。现阶段投资于已具相当规模,技术力量雄厚的企业和中后期技术含量相对低的项目不失为一种好的选择。 本文的发表在当前的“非典”时期殊具现实意义。
The author analyzes the status quo of China’s pharmaceutical industry, and uses cluster analysis method, according to the characteristics of China’s pharmaceutical industry, based on the performance of the top companies in the pharmaceutical industry on the impact of biomedical industry investment opportunities in the empirical analysis of the factors, and then look forward to China’s pharmaceutical industry The development prospects of venture capital and points out the possible entry point for venture capital. The author finds that the characteristics of the product and its market positioning play a key role in the success or failure of the company’s operation in the pharmaceutical industry. As long as the product performance is good and the market position is reasonable, investment in chemical pharmaceuticals, biopharmaceuticals and Chinese medicine industry may be encouraged. At this stage, the main factors affecting the investment opportunities in the industry are product technical risks and market risks. Non-patent and OTC drugs, biotechnology and Chinese medicine, computer-related biochip and other fields, investors should focus on. At this stage to invest in a considerable scale, strong technical force of enterprises and the relatively low technical content in the latter part of the project may well be a good choice. The publication of this article is of practical significance in the current “SARS” period.